Abstract
Patients with gastric carcinoma and serosal invasion were randomized into a "treatment" or "control" protocol after R0 resection ("prophylactic group", n = 45) or palliative resection without cytoreductive surgery in cases with localized peritoneal seeding ("therapy group", n = 19). The results of a planned interim analysis after 5 years indicate that MMC-CH therapy causes little systemic toxicity but enhances the rate of intraabdominal infections (9/33 vs. 2/31, p < 0.01) and reoperations (5/33 vs 0/31, p < 0.05). The preliminary survival analysis shows a possible prognostic effect following R0 resection after 24 months (p < 0.05) and 36 months (p < 0.07), but no benefit for the palliative procedures, which caused the withdrawal of the "therapy" study arm.
Publication types
-
Clinical Trial
-
Comparative Study
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / pathology
-
Adenocarcinoma / secondary*
-
Adenocarcinoma / surgery
-
Adult
-
Aged
-
Antibiotics, Antineoplastic / administration & dosage*
-
Antibiotics, Antineoplastic / adverse effects
-
Charcoal / administration & dosage*
-
Charcoal / adverse effects
-
Chemotherapy, Cancer, Regional Perfusion
-
Combined Modality Therapy
-
Female
-
Humans
-
Male
-
Middle Aged
-
Mitomycin / administration & dosage*
-
Mitomycin / adverse effects
-
Neoplasm Invasiveness
-
Neoplasm Seeding
-
Palliative Care
-
Peritoneal Neoplasms / drug therapy
-
Peritoneal Neoplasms / pathology
-
Peritoneal Neoplasms / secondary*
-
Peritoneal Neoplasms / surgery
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology
-
Stomach Neoplasms / surgery
-
Treatment Outcome
Substances
-
Antibiotics, Antineoplastic
-
Charcoal
-
Mitomycin